Abstract
Pediatric sarcomas are aggressive tumors seen in childhood that utilize advanced imaging methods for diagnosis, staging, and assessment of treatment response. Each subtype’s distinct clinical-histopathological features and metastatic potential present unique challenges. Nuclear medicine applications provide morphological and metabolic information for whole-body staging, restaging, visualization of viable tumor foci, guidance for biopsy when necessary, and assessment of therapeutic response. With these features, nuclear medicine imaging plays a complementary role to other imaging modalities. This review discusses the most common pediatric sarcomas, the nuclear medicine methods used, and new targets/future perspectives.
Keywords: Pediatric sarcoma, Tc-99m MDP bone scintigraphy, PET/CT
References
Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70:443-459.
Cao J, An Q, Wang L. Pediatric sarcomas. Oncol Lett. 2018;15:1397-1402. Retraction in: Oncol Lett. 2018;15:5391.
Yıldız Y, Sağlık Y. Kemik ve yumuşak doku tümörlerinde biopsi. TOTBİD Dergisi. 2003;2:37-43.
Robert K, Heck Jr. Tümörlerin genel özellikleri. In: Canale ST, Beaty JH, editors. Campbell’s operative orthopaedics. Vol 1. 11th ed. Philedelphia: Mosby; 2011. p. 775-854.
Bestic JM, Wessell DE, Beaman FD, et al. Expert panel on musculoskeletal imaging. ACR appropriateness criteria® primary bone tumors. J Am Coll Radiol. 2020;17:S226-S238.
Kaya H, Daştan AE. Ortopedist gözüyle nükleer tıptan beklentiler. Nucl Med Semin. 2022;8:8-14.
Tamsel İ. Primer ve metastatik iskelet lezyonlarının değerlendirilmesinde radyolojik yaklaşım. Nucl Med Semin. 2022;8:15-24.
Akbulut A. Primer kemik ve yumuşak doku tümörlerinde moleküler görüntüleme. Korkmaz M, editör. Kas iskelet sistemi hastalıklarında moleküler görüntüleme. 1. Baskı. Ankara: Türkiye Klinikleri; 2023. p.15-22.
Yanarateş A, Ömür Ö. Primer kemik ve yumuşak doku tümörleri: güncel algoritmalarda nükleer tıp. Nucl Med Semin. 2022;8:82-91.
Expert Panel on Musculoskeletal Imaging; Ahlawat S, Lenchik L, Baker JC, et al. ACR appropriateness criteria® suspected primary bone tumors: 2024 update. J Am Coll Radiol. 2025;22:S440-S454.
Costelloe CM, Madewell JE. Radiography in the initial diagnosis of primary bone tumors. AJR Am J Roentgenol. 2013;200:3-7.
Kindblom LG. Bone tumors: epidemiology, classification, pathology. In: Davies AM, Sundaram M, James SL editors. Imaging of bone tumors and tumor like lesions. Berlin: Springer-Verlag; 2009. p.1-15. 24.
Kaya H, Sabah D, Keçeci B ve ark. Kemik ve yumuşak doku sarkomları epidemiyolojisi ve genel sağ kalım özellikleri. Ege Tıp Dergisi / Ege Journal of Medicine. 2019;58: Ek Sayı Supplement 88-104.
Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012;2012:627254.
Biermann JS, Hirbe A, Ahlawat S, et al. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:e250017.
Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123-32.
Leavey, Patrick J. MD; Day, Michael D. MD; Booth, Timothy MD; Maale, Gerhard MD. Skip Metastasis in Osteosarcoma. Journal of Pediatric Hematology/Oncology 25:806-808, October 2003.
Oh C, Bishop MW, Cho SY, et al. 18F-FDG PET/CT in the management of osteosarcoma. J Nucl Med. 2023;64:842-851.
Liu F, Zhang Q, Zhou D, Dong J. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma:a meta-analysis of 26 studies. BMC Cancer. 2019;19:323.
Im HJ, Zhang Y, Wu H, et al. Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: a hypothesis-generating study. Radiology. 2018;287:303-312.
Hongtao L, Hui Z, Bingshun W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Surg Oncol. 2012;21:e165-e170.
Fan Z, Wang T, Zou L, Liu D. Comparison of the diagnostic value of 18F-NaF PET/CT and 99mTc-MDP SPECT for bone metastases: a systematic review and meta-analysis. Transl Cancer Res. 2023;12:3166-3178.
Sabah D. Ewing Sarkomu. TOTBİD Dergisi. 2014;13:247-251.
Wlasak R, Sim FH. Ewing’s sarcoma. Orthop Clin North Am. 1996;27:591-603.
Widhe B, Widhe T. Osteosarkom ve Ewing sarkomunda ilk semptomlar ve klinik özellikler. J Bone Joint Surg Am. 2000;82:667-674.
Wells, Matthew E. DO; Eckhoff, Michael D. MD; Davis, William Pharm D; Singh, Vishwajeet PhD; Rajani, Rajiv MD; Polfer, Elizabeth M. MD. Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States. JAAOS: Global Research and Reviews 8:e24.00281, October 2024.
Guimarães JB, Rigo L, Lewin F, Emerick A. The importance of PET/CT in the evaluation of patients with Ewing tumors. Radiol Bras. 2015;48:175-180.
Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A, Schöder H. Pediatric bone sarcoma: diagnostic performance of 18 F-FDG PET/CT versus conventional imaging for initial staging and follow-up. AJR Am J Roentgenol. 2015;204:153-160.
Bailly C, Leforestier R, Campion L, et al. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. Plos One. 2017;12:e0183841.
Seth N, Seth I, Bulloch G, et al.18F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: a systematic review and meta-analysis. Pediatr Blood Cancer. 2022;69:e29415.
Albano D, Dondi F, Schumacher RF, D’Ippolito C, Porta F, Giubbini R, Bertagna F. Clinical and prognostic role of 18F-FDG PET/CT in pediatric Ewing sarcoma. J Pediatr Hematol Oncol. 2020;42:e79-e86.
Palmerini E, Colangeli M, Nanni C, et al. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging. 2017;44:215-223.
Denecke T, Hundsdörfer P, Misch D, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37:1842-1853.
Sharma P, Khangembam BC, Suman KCS, et al. Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. Eur J Nucl Med Mol Imaging. 2013;40:1036-1043.
Gabriel M, Rubello D. 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value? Nucl Med Commun. 2016;37:3-8.
Mercolini F, Zucchetta P, Jehanno N, et al. Role of 18F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group. Eur J Cancer. 2021;155:155-162.
Federico SM, Spunt SL, Krasin MJ, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatric Blood Cancer. 2012;60:1128-1134.
Baum SH, Frühwald M, Rahbar K, Wessling J, Schober O, Weckesser M. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med. 2011 Oct;52(10):1535-1540.
Casey DL, Wexler LH, Fox JJ, et al. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90:1136-1142.
Harrison DJ, Chi YY, Tian J, et al. Metabolic response as assessed by 18F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer Med. 2021;10:857-866.
van Ewijk R, Schoot RA, Sparber-Sauer M, et al. Cooperative Weichteilsarkom Studiengruppe Imaging Group, the European Society of Paediatric Radiology Oncology Task Force and the European Paediatric Soft Tissue Sarcoma Study Group Imaging Committee. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma - joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. Pediatr Radiol. 2021;51:1940-1951.
Kessler L, Ferdinandus J, Hirmas N, et al. 68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial. J Nucl Med. 2022;63:89-95.
Taddio MF, Doshi S, Masri M, et al. Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. Eur J Nucl Med Mol Imaging. 2024;51:4026-4037.
Crompton JG, Armstrong WR, Eckardt MA, et al. 18F-FLT PET/CT as a Prognostic imaging biomarker of disease-specific survival in patients with primary soft-tissue sarcoma. J Nucl Med. 2022;63:708-712.
Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.
Gilheeney SW, Lyden DC, Sgouros S, et al. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer. 2007;49:261-265.
Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer. 2021;28:R81-R93.
